1. Generics Bulletin
  2. >>Business

Torrent On Acquisition And Licensing Strategy, Vonoprazan Trajectory

FY25: 5-10 Product Approvals Expected In US

 
• By Vibha Ravi

Amid deals activity in India, Torrent Pharma executives spelt out their acquisition expectations and licensing strategy while an in-licensed Takeda brand did well in Q1 of FY25. The US growth trajectory is seen determined by five to ten product approvals expected this fiscal.

Strategy
Torrent Spells Out Its Acquisition, Licensing Strategy • Source: Shutterstock

Torrent Pharmaceuticals executives recently commented on their acquisition strategy and expectations even as speculation around deals for Indian companies like JB Chemicals & Pharmaceuticals and Bharat Serums And Vaccines Limited were doing the rounds, with Torrent also in the mix of rumored bidders.

Recently, Mankind Pharma Ltd. bought out 100% of BSV for an enterprise value of about INR136.3bn ($1.6bn). (Also see "Podcast: Amid Talk Of KKR Stake Sale, JB CEO Stresses Business As Usual" - Scrip, 4 June, 2024

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

Sandoz Slims Down Pembrolizumab Trial As Regulators Streamline Requirements

 
• By Dave Wallace

As Sandoz continues development of its planned pembrolizumab biosimilar rival to Keytruda, the company has revealed plans to slim down its Phase III trial amid the latest moves from regulators towards streamlining clinical study requirements for biosimilar registration.

Amgen’s Aflibercept Starts Strong As Regeneron Counts Cost Of Eylea Competition

 
• By Dean Rudge

Amgen told investors during its 1 May first-quarter earnings call that its Pavblu biosimilar to Eylea 2mg had flown out of the gates, while Regeneron admitted “some difficult news related to our retinal franchise.”

BGMA Becomes Medicines UK

 
• By Dave Wallace

The UK generics and biosimilars industry will now be represented by Medicines UK, the new name for the former British Generic Manufacturers Association.